Home/Filings/4/0001193125-25-308804
4//SEC Filing

Hickey Benjamin 4

Accession 0001193125-25-308804

CIK 0001971543other

Filed

Dec 4, 7:00 PM ET

Accepted

Dec 5, 9:16 AM ET

Size

10.3 KB

Accession

0001193125-25-308804

Insider Transaction Report

Form 4
Period: 2025-12-05
Transactions
  • Disposition to Issuer

    Stock Option (right to buy)

    2025-12-058,6370 total
    Exercise: $2.56Exp: 2035-06-10Ordinary Shares (8,637 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2025-12-058,4620 total
    Exercise: $3.35Exp: 2034-05-29Ordinary Shares (8,462 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2025-12-0515,0210 total
    Exercise: $3.61Exp: 2033-12-13Ordinary Shares (15,021 underlying)
Footnotes (2)
  • [F1]This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time").
  • [F2]Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.

Documents

1 file

Issuer

Mural Oncology plc

CIK 0001971543

Entity typeother

Related Parties

1
  • filerCIK 0001753055

Filing Metadata

Form type
4
Filed
Dec 4, 7:00 PM ET
Accepted
Dec 5, 9:16 AM ET
Size
10.3 KB